# LimmaTech Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/limmatech-biologics

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.lmtbio.com
- Total disclosed funding: $39M
- Latest round: Series A (Feb 1, 2024)
- Investors on record: 4

## About

Based in Zurich, Switzerland, and founded in 2015 by Paul Wolfrom and Michael Kowarik, LimmaTech Biologics AG, a.k.a. LimmaTech, operates as a biopharmaceutical company that focuses on the development of vaccines against infections caused by antimicrobial resistance (AMR) and sexually transmitted diseases. In February 2024, LimmaTech Biologics AG raised USD 3 million in a Series A funding led by Tenmile. As of August 2024, Franz-Werner Haas is the CEO of the company.

The company leverages its proprietary vaccine technology platform, where it utilizes a genetically engineered E. coli strain to produce vaccine candidates in a single, scalable process.

The company plans to use its proceeds from February 2024 funding to accelerate the preclinical and clinical development of its pipeline of potential vaccine candidates using its platform.

## Funding rounds

- Series A, Feb 1, 2024, $3M — Tenmile
- Series A, Oct 9, 2023, $36M — Novo Holdings, AXA IM Alts, Adjuvant Capital

## Investors

- Novo Holdings — Series A
- AXA IM Alts — Series A
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series A
- Tenmile (https://capitalatlas.ai/funds/tenmile) — Series A